A phase I/II study of Cetuximab combined with irinotecan and S-1 as first line therapy in metastatic colorectal cancer patients with KRAS wild type
Ontology highlight
ABSTRACT: Interventions: Cetuximab; bi-weekly administration 500mg/m2. Irinitecan is administered as an intravenous infusion at a dose of 120mg/m2 on day 1 and 15. And TS-1 is orally administered on days 1-14 of a 28-day cycle. Administration dose of TS-1 is based BSA : BSA<1.25m2, 40mg twice daily; 1.25-1.5m2, 50mg twice daily; >1.5m2, 60mg twice daily.
Primary outcome(s): Phase I study To evaluate feasibility Phase II study Response rate
Study Design: Single arm Non-randomized
DISEASE(S): Advanced Colorectal Cancer
PROVIDER: 2619853 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA